🔍

Syschem India Ltd (531173)

📊 BSE: 531173 🏢 Pharmaceuticals 📢 Latest filing: 16 Oct 2026 📝 Analysis written: 13 Nov 2025

Q2 FY27 results

📅 Next results: 26 Oct 2026 (board meeting)

Syschem India Ltd's board meets on 26 Oct 2026 to consider its Q2 FY27 results (July-September 2026).

In its latest reported quarter, Q1 FY27, Syschem India's revenue was ₹126 Cr (+15.2% year on year, -42.6% on the previous quarter), and net profit ₹-1.7 Cr (against a profit a year earlier); the operating margin was 0.4%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹126	+15.2%	-42.6%
Operating profit	₹0.5	-77.8%	-94.2%
Net profit	₹-1.7	to loss	to loss
EPS (₹)	-0.31	to loss	to loss
Operating margin	0.4%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

Syschem Pays ₹1.25 Cr Settlement Amount to Lotus Builders to Settle NCLT Dispute

🟢 POSITIVE ⭐ 5/10

LEGAL 📅 16 Oct 2026, 01:25 PM

Syschem (India) Limited has paid the full and final settlement amount of ₹1.25 crore to M/s Lotus Builders pursuant to a settlement agreement. Following this payment, the company will file appropriate applications before the Hon'ble National Company Law Tribunal (NCLT) for the withdrawal and disposal of the pending matter. The payment resolves an ongoing legal overhang, representing approximately 1% of the company's ₹125 crore market cap and 20.8% of its TTM net profit of ₹6 crore.

Full and final settlement amount of ₹1,25,00,000 (₹1.25 crore) paid to M/s Lotus Builders
Application being filed before the Hon'ble NCLT for withdrawal/disposal of the pending dispute
Settlement follows earlier disclosure intimations dated February 26, 2024, and June 4, 2026
Settlement cash outflow of ₹1.25 crore compares against TTM PAT of ₹6 crore

💡 Track the formal dismissal order from the NCLT disposing of the case against the company.

Syschem India Reports Nil Deviation in Utilization of ₹16 Cr Raised via Preferential Issue

🟡 NEUTRAL ⭐ 3/10

FUNDRAISE 📅 16 Oct 2026, 12:20 PM

Syschem India Limited has submitted its Statement of Deviation/Variation under Regulation 32 for the quarter ended September 30, 2026. The company confirmed that out of the total ₹8,183.00 Lakhs originally planned, it has raised ₹159,954,375 (₹15.99 crore) on July 7, 2026 via a preferential issue. The entire raised amount of ₹15.99 crore has been deployed toward working capital requirements, in line with stated objectives. The Audit Committee noted zero deviation or variation in fund usage.

Total funds raised via preferential issue amounted to ₹159,954,375 on July 7, 2026
Entire raised amount of ₹1599.54 Lakhs utilized toward meeting working capital requirements
Nil deviation or variation reported against stated object allocation
Total planned allocation under the scheme was ₹8,183.00 Lakhs across capex, debt repayment, and working capital

💡 Track subsequent quarterly filings to monitor the deployment of remaining planned fundraises toward stated capex (₹500 Lakhs) and security deposit repayments.

Syschem India Appoints Suninder Veer Singh as MD; Bansal Vijay & Assoc Named Auditor for 5 Years

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 08 Oct 2026, 04:25 PM

Syschem India announced management reshuffles and auditor appointments approved by shareholders at its 33rd AGM on September 30, 2026. Mr. Suninder Veer Singh has taken charge as Managing Director, moving from Whole-Time Director, while former MD Mr. Ranjan Jain transitioned to Whole-Time Director. Additionally, M/s Bansal Vijay & Associates was appointed as Statutory Auditors for a 5-year tenure following the resignation of the outgoing auditor. The leadership changes come at a time when the company reported a net loss of Rs 1.67 Cr in Q1 FY27 (ended June 2026) despite TTM revenues of Rs 590 Cr.

Mr. Suninder Veer Singh redesignated from Whole-Time Director to Managing Director effective September 30, 2026
Mr. Ranjan Jain stepped down as MD to take charge as Whole-Time Director effective September 30, 2026
M/s Bansal Vijay & Associates, Chartered Accountants, appointed as Statutory Auditors for a 5-year term
Board meeting commenced at 15:20 IST and concluded at 16:15 IST on October 08, 2026

💡 Track whether the top leadership realignment leads to improved operating profit margins, especially after Q1 FY27 posted an operating profit of just Rs 0.55 Cr on Rs 125.95 Cr revenue.

Syschem India Appoints Suninder Veer Singh as MD; Replaces Statutory Auditor

🟡 NEUTRAL ⭐ 5/10

MANAGEMENT 📅 01 Sep 2026, 12:29 PM

Syschem India announced leadership re-designations and a change in statutory auditors during its board meeting on September 1, 2026. Mr. Suninder Veer Singh has been appointed as Managing Director, while former MD Mr. Ranjan Jain will transition to Whole-Time Director, both for a 5-year term starting September 30, 2026, with a remuneration of up to Rs 7,00,000 per month each. Additionally, statutory auditor M/s STAV & Co resigned due to the expiry of their Peer Review Certificate, and M/s Bansal Vijay & Associates was appointed as the new auditor at an annual fee of Rs 2,50,000 plus GST, subject to shareholder approval at the AGM on September 30, 2026.

Suninder Veer Singh appointed as Managing Director for a 5-year term effective September 30, 2026
Ranjan Jain transitions from Managing Director to Whole-Time Director for a 5-year term
Approved monthly remuneration of up to Rs 7,00,000 each for the MD and Whole-Time Director for 3 years
Statutory auditor M/s STAV & Co resigned w.e.f. August 31, 2026 due to non-renewal of Peer Review Certificate
M/s Bansal Vijay & Associates appointed as new statutory auditors for a 5-year term at Rs 2,50,000 per annum

💡 Track shareholder voting outcomes on the management appointments and auditor approval at the 33rd Annual General Meeting scheduled for September 30, 2026.

Syschem India Statutory Auditor STAV & Co Resigns Effective 31 August 2026

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 31 Aug 2026, 03:18 PM

Syschem India Limited announced the resignation of its Statutory Auditor, M/s STAV & Co., Chartered Accountants, effective 31 August 2026 after business hours. The resignation was tendered due to the expiration and non-renewal of the firm's Peer Review Certificate on 31 August 2026, rendering them ineligible under regulatory norms. The auditing firm confirmed there are no other underlying reasons for their exit. The company is currently taking steps to appoint a new eligible statutory auditor.

M/s STAV & Co. resigned as Statutory Auditor effective 31 August 2026 post-business hours.
Resignation prompted solely by the expiry and non-renewal of the auditor's Peer Review Certificate on 31 August 2026.
Auditor explicitly confirmed no other reasons for resignation.
Process initiated to appoint a new Statutory Auditor under the Companies Act, 2013 and SEBI LODR.

💡 Track the upcoming board appointment of the replacement statutory auditor to ensure smooth regulatory compliance and timely financial audit transitions.

Syschem India Clarifies Typographical Error in Q1 FY27 Investor Presentation

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 10 Aug 2026, 11:34 AM

Syschem India Ltd has issued a clarification regarding its Investor Presentation originally uploaded on August 8, 2026. The company identified a typographical error where 'Q2 (Quarter-2)' was mentioned instead of 'Q1 (Quarter-1)' for the Financial Year 2026-27. Management confirmed that this error is purely administrative and does not alter any financial figures, operational data, or results previously disclosed. A corrected version of the presentation is being uploaded to the exchange.

Clarification issued on August 10, 2026, regarding a presentation filed on August 8, 2026
Correction involves changing all 'Q2' references to 'Q1' for the FY 2026-27 period
Management confirms 0% impact on reported financial results or operational disclosures
Company is in the process of filing a corrected Investor Presentation on the BSE portal

💡 Investors should ensure they are reviewing the corrected version of the presentation for Q1 FY27 performance metrics. No further action is required as the underlying financial data remains unchanged.

Syschem India Q2 FY27: PBT swings to Rs 1.45 Cr loss amid forex volatility

🔴 NEGATIVE ⭐ 6/10

EARNINGS 📅 08 Aug 2026, 05:10 PM

Syschem India reported a challenging Q2 FY26-27 (June 2026 quarter), with Profit Before Tax (PBT) swinging to a loss of Rs 1.45 Cr from a profit of Rs 5.60 Cr in the March 2026 quarter. The company cited significant foreign exchange fluctuations and global economic uncertainties as primary drivers for the moderation in financial performance. Despite the quarterly loss, the company is proceeding with its manufacturing expansion at the Kalka facility for B-lactam antibiotics and targeting WHO-GMP certification. The company remains debt-free with a TTM revenue of Rs 574 Cr, though operating margins remain thin at 3.7%.

Profit Before Tax (PBT) declined to a loss of Rs 1.45 Cr in June FY26-27 compared to a profit of Rs 5.60 Cr in March FY25-26.
EBITDA moderated to Rs 1.26 Cr for the June FY26-27 quarter, down from Rs 2.48 Cr in the preceding March quarter.
Manufacturing expansion is underway at the Kalka, Haryana facility to produce Cloxacillin, Dicloxacillin, and Flucloxacillin.
The company is actively pursuing WHO-GMP certification to enhance global regulatory compliance and market access.
Geographic footprint now spans 13 international markets including China, Thailand, Nigeria, and Bangladesh.

💡 Investors should monitor the stabilization of operating margins and the impact of forex management in upcoming quarters. The key execution milestone to watch is the completion and WHO-GMP certification of the Kalka facility expansion, which is critical for moving into higher-margin regulated markets.

Syschem India publishes newspaper advertisements for Q1 FY27 financial results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 06 Aug 2026, 04:05 PM

Syschem India Ltd has published its unaudited financial results for the quarter ended June 30, 2026, in Jansatta and Financial Express on August 5, 2026. This filing is a routine regulatory requirement under SEBI (LODR) Regulations, 2015, following the board's approval of the quarterly performance. While the specific quarterly figures in the provided newspaper clipping are partially illegible, the company enters this period with a TTM revenue of ₹574 Cr and a thin operating margin of 3.7%. Investors should focus on the full financial statement for detailed performance metrics.

Published results in Jansatta (Hindi) and Financial Express (English) on August 5, 2026
Relates to the unaudited financial results for the quarter ended June 30, 2026
Compliance filing under Regulation 47(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Company maintains a TTM revenue base of ₹574 Cr as per latest available context

💡 Investors should review the detailed quarterly results filing rather than the newspaper summary to monitor the operating profit margin (OPM), which stood at 3.7% TTM, and the progress of the Kalka facility expansion.

31.97 Lakh Warrants Lapse; Syschem India Forfeits Subscription Amount

🟡 NEUTRAL ⭐ 4/10

FUNDRAISE 📅 05 Aug 2026, 12:28 PM

Syschem India clarified that 31,97,500 convertible warrants out of the 1,67,00,000 allotted in February 2025 have lapsed as they were not exercised within the 18-month window. The upfront subscription amount for these lapsed warrants has been forfeited by the company in accordance with SEBI ICDR Regulations. The remaining 1,35,02,500 warrants, including those held by the promoter group, were successfully converted into equity shares after full payment. This represents a ~19% shortfall in the total potential capital infusion from this specific warrant tranche.

31,97,500 warrants lapsed out of the total 1,67,00,000 allotted on February 4, 2025
The 18-month conversion period expired on August 4, 2026, leading to the lapse
Approximately 19.1% of the total warrants issued failed to convert into equity
Upfront subscription amounts for the lapsed warrants are forfeited to the company
Promoters and other holders successfully converted the remaining 1.35 crore warrants

💡 Investors should review the upcoming shareholding pattern to assess the final dilution impact and the updated promoter stake following the successful conversion of the majority of the warrants.

Syschem India Reports Q1 Net Loss of ₹1.67 Cr; Forfeits ₹3.92 Cr in Lapsed Warrants

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 02:35 PM

Syschem India reported a weak start to FY27, swinging to a net loss of ₹1.67 Cr in Q1 compared to a profit of ₹1.67 Cr in the same period last year. Revenue remained stagnant at ₹125.95 Cr, while total expenses rose to ₹127.45 Cr, primarily driven by high raw material costs. Separately, the company forfeited ₹3.92 Cr after 31.97 lakh warrants lapsed as holders failed to exercise their conversion rights by the August 3, 2026 deadline. This forfeiture provides a one-time boost to reserves but highlights a lack of capital infusion from the warrant holders.

Reported a net loss of ₹1.67 Cr in Q1 FY27 against a profit of ₹1.67 Cr in Q1 FY26
Revenue from operations stood at ₹125.95 Cr, showing a marginal decline from ₹126.76 Cr YoY
Forfeited ₹3.91,69,375 (₹3.92 Cr) due to the lapse of 31,97,500 convertible warrants
Total expenses of ₹127.45 Cr exceeded total income of ₹126.00 Cr for the quarter
Warrant conversion window of 18 months expired on August 3, 2026, without full exercise by three major allottees

💡 Investors should monitor the company's ability to stabilize margins and the progress of the Kalka facility expansion, which is critical for future growth. The swing to a loss despite stable revenue suggests significant cost-side pressure that needs addressing.

Syschem India Reports ₹1.67 Cr Net Loss in Q1; Forfeits ₹3.92 Cr from Lapsed Warrants

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 01:36 PM

Syschem India reported a weak start to FY27, swinging to a net loss of ₹1.67 Cr in Q1 compared to a profit of ₹1.67 Cr in the same period last year. Revenue from operations remained stagnant at ₹125.95 Cr, while total expenses rose to ₹127.45 Cr, exceeding total income. Separately, the company forfeited ₹3.92 Cr (25% upfront consideration) as 31.97 lakh warrants lapsed without being converted into equity by the August 3, 2026 deadline. This indicates a failure to complete a portion of the planned capital infusion.

Net loss of ₹1.67 Cr in Q1 FY27 compared to a net profit of ₹1.67 Cr in Q1 FY26
Revenue from operations remained flat YoY at ₹125.95 Cr vs ₹126.76 Cr
Forfeiture of ₹3.92 Cr following the lapse of 31,97,500 convertible warrants
Employee benefit expenses surged 111% YoY to ₹4.04 Cr from ₹1.91 Cr
Finance costs increased significantly to ₹48.95 Lakhs from ₹3.91 Lakhs in the year-ago quarter

💡 Investors should monitor the execution timeline of the Kalka facility expansion and the company's ability to manage rising employee and finance costs amidst stagnant revenue.

Syschem India reports Q1 Net Loss of ₹1.67 Cr; forfeits ₹3.92 Cr as warrants lapse

🔴 NEGATIVE ⭐ 7/10

EARNINGS 📅 04 Aug 2026, 01:30 PM

Syschem India reported a net loss of ₹1.67 Cr for Q1 FY27, a significant downturn from a profit of ₹1.67 Cr in the same quarter last year. Revenue remained stagnant at ₹125.95 Cr compared to ₹126.76 Cr YoY. Additionally, the company forfeited ₹3.92 Cr (25% upfront consideration) as 31,97,500 warrants lapsed after holders failed to exercise conversion rights by the August 3, 2026 deadline. The swing to a loss was driven by total expenses of ₹127.45 Cr exceeding total income.

Net loss of ₹1.67 Cr in Q1 FY27 vs a profit of ₹1.67 Cr in Q1 FY26
Forfeiture of ₹3,91,69,375 following the lapse of 31,97,500 convertible warrants
Revenue from operations stood at ₹125.95 Cr, a marginal decline of 0.6% YoY
Total expenses rose to ₹127.45 Cr, with cost of materials consumed at ₹104.64 Cr
Warrant holders forfeited their 25% upfront payment rather than converting to equity by the 18-month deadline

💡 Investors should monitor the company's ability to pass on raw material costs, as the current quarter shows operational stress with expenses exceeding income. The failure of warrant holders to convert suggests a lack of confidence in the current market price relative to the warrant exercise price.

Aug 4 Board Meeting to approve Q1 FY27 results for Syschem India

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 22 Jul 2026, 12:32 PM

Syschem India has scheduled a board meeting on August 4, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The company is coming off a high-revenue March 2026 quarter (Rs 219.35 Cr), which significantly boosted its TTM revenue to Rs 574 Cr. Given the thin operating profit margin of 3.7%, investors will be closely watching for margin stability and the impact of raw material costs. The trading window for designated persons is currently closed and will reopen 48 hours after the results are declared.

Board meeting scheduled for August 4, 2026, to approve Q1 results.
Company reported a significant revenue of Rs 219.35 Cr in the preceding quarter (Mar 2026).
TTM revenue stands at Rs 574 Cr, which is nearly 3x its current market capitalization of Rs 193 Cr.
Operating profit margins remain thin at 3.7%, making earnings sensitive to input cost changes.

💡 Monitor the results on August 4 to verify if the high revenue run-rate from Q4 FY26 is sustainable and if the company has managed to improve its 3.7% operating margin.

March 8, 2027: Shareholders Reject Management Re-designation; Existing Terms to Continue

🔴 NEGATIVE ⭐ 7/10

MANAGEMENT 📅 17 Jul 2026, 01:48 PM

Syschem India's board has acknowledged that shareholders rejected postal ballot resolutions intended to re-designate Mr. Ranjan Jain as Whole-time Director and Mr. Suninder Veer Singh as Managing Director. Consequently, the current leadership structure and remuneration terms, originally set in 2022 and updated in January 2025, will remain in effect until March 8, 2027. This rejection by shareholders indicates a lack of consensus on the proposed management shuffle and associated compensation changes. The company had previously disclosed the scrutinizer's report on July 14, 2026.

Shareholders rejected re-designation and remuneration fixation for two key directors via Postal Ballot on July 14, 2026
Existing appointments of Mr. Ranjan Jain (MD) and Mr. Suninder Veer Singh (WTD) remain valid until March 8, 2027
Revised remuneration approvals from the EGM held on January 20, 2025, will continue to prevail
The original appointments were approved by shareholders on April 9, 2022, effective from March 9, 2022

💡 Monitor for any follow-up communications from the board regarding the reasons for shareholder dissent and watch for revised management proposals before the 2027 deadline.

Syschem India opens special window for share transfer re-lodgement until Feb 4, 2027

🟡 NEUTRAL ⭐ 2/10

REGULATORY 📅 08 Jul 2026, 05:28 PM

Syschem India Ltd has announced a special one-year window for shareholders to re-lodge share transfer requests, effective from February 05, 2026, to February 04, 2027. This initiative follows a SEBI circular aimed at facilitating the ease of investing and safeguarding investor rights. The window specifically applies to transfer deeds that were originally lodged before April 1, 2019, but were subsequently rejected or remained pending. This is a procedural update to assist investors with legacy physical shareholding issues.

Special window for re-lodgement is open for a period of one year from February 05, 2026, to February 04, 2027
Applies to transfer deeds originally lodged before April 1, 2019, which were rejected or pending
Action taken pursuant to SEBI Circular dated February 05, 2026
Newspaper advertisements published on July 08, 2026, to create investor awareness

💡 Investors holding physical shares with unresolved transfer issues from before April 2019 should contact the company's RTA to utilize this window before February 04, 2027. No action is required for investors holding shares in demat form.

View All 531173 Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company operates in a single segment (APIs) and reported a 24% quarter-over-quarter increase in revenue for the quarter ending June 2025 compared to June 2024. However, a modest dip was noted in June 2025 compared to March 2025 due to weaker demand early in the financial year.

Geographic Revenue Split

Not disclosed in available documents, though the company targets both domestic and international markets for its API products.

Profitability Margins

Operating Profit Margin significantly decreased from 1.76% in FY2023-24 to 0.26% in FY2024-25. Net Profit Margin also fell from 1.18% to 0.1191% over the same period, primarily due to a reduction in overall profitability and increased operational costs.

EBITDA Margin

EBITDA improved in the June 2025 quarter compared to previous periods, though specific percentage margins for the full year FY2024-25 show a downward trend in core profitability as operating margins collapsed to 0.26%.

Capital Expenditure

The company is currently constructing a new manufacturing unit in Kalka, Haryana, for B-lactam antibiotics. Borrowing powers have been increased to INR 150 Crores to support expansion and business growth.

Credit Rating & Borrowing

The Debt-Equity ratio improved from 0.01 to 0.00 in FY2024-25 following the repayment of unsecured loans. However, the Interest Coverage Ratio saw a drastic decline from 2571.69 to 18.06, indicating significantly higher interest obligations relative to earnings.

⚙️ Operational Drivers

Raw Materials

Key raw materials include inputs for Amoxycillin Trihydrate, Ampicillin Trihydrate, and Cloxacillin Sodium. Specific names and percentage of total cost are not disclosed, but raw material volatility is cited as a major impact on cost structure.

Capacity Expansion

Production capacity was scaled up by 95% by the end of March 2025 and 81% by June 2025 compared to June 2024. A new plant in Kalka, Haryana, is currently under construction to further enhance capacity for cloxacillin, dicloxacillin, and flucloxacillin.

Raw Material Costs

Raw material costs are subject to high volatility. The company has initiated strategic sourcing and lean manufacturing practices to mitigate financial pressure and improve margins which were squeezed to 0.26% in FY25.

Manufacturing Efficiency

The company demonstrated enhanced operational capacity with a 95% production scale-up by March 2025. The facility in Kalka is ISO-certified and aligned with cGMP standards.

📈 Strategic Growth

Expected Growth Rate

9-12%

Growth Strategy

Growth will be achieved through the strategic expansion of the Kalka facility to produce B-lactam antibiotics (Cloxacillin, Dicloxacillin, and Flucloxacillin) under WHO-GMP guidelines. The company is also focusing on backward integration and process innovation to remain competitive against aggressive peer pricing.

Products & Services

Active Pharmaceutical Ingredients (APIs) including Amoxycillin Trihydrate, Ampicillin Trihydrate, and Cloxacillin Sodium.

New Products/Services

New products include Cloxacillin, Dicloxacillin, and Flucloxacillin, which will be manufactured at the upcoming WHO-GMP compliant facility.

Market Expansion

Targeting rising domestic and international demand for B-lactam antibiotics to contribute to India's pharmaceutical self-reliance vision.

Strategic Alliances

The company has a significant partnership with Indosol Export for transactions involving the sale and purchase of goods up to a maximum value of INR 100 Crores.

🌍 External Factors

Industry Trends

The Indian pharmaceutical sector is expected to reach US$ 100 billion by 2025. There is a notable shift toward chronic therapies such as cardiovascular, anti-diabetes, and anti-cancer treatments.

Competitive Landscape

The API industry is highly competitive with both domestic and international players offering similar products, leading to commoditization pressures.

Competitive Moat

Moat is built on ISO-certified and cGMP-aligned manufacturing facilities, backward integration, and a dedicated R&D division. These provide a quality-based differentiation, though sustainability is challenged by aggressive peer pricing.

Macro Economic Sensitivity

Highly sensitive to the performance of the Indian economy and international pharmaceutical markets, as well as medicine spending trends which are projected to grow 9-12%.

Consumer Behavior

Increasing demand for chronic therapy medicines and evolving regulatory quality expectations are driving shifts in product portfolios.

Geopolitical Risks

Risks include clinical-trial execution, drug approval delays, and global commercial practice changes in a politically and economically turbulent environment.

⚖️ Regulatory & Governance

Industry Regulations

Operations must comply with WHO-GMP guidelines, cGMP standards, and ISO certifications. Regulatory requirements significantly impact product approvals and manufacturing standards.

Environmental Compliance

The company is committed to sustainable practices and reducing environmental impact across the value chain, though specific ESG costs are not disclosed.

Legal Contingencies

The secretarial audit reports compliance with the Companies Act 2013 and SEBI regulations. No specific pending court case values or major legal disputes were disclosed.

⚠️ Risk Analysis

Key Uncertainties

Key risks include the inability to attract/retain skilled technical personnel, raw material cost volatility, and pricing pressure from disruptive business models in the branded generics sector.